Factor v leiden and antiphospholipid antibodies in either mothers or infants increase the risk for perinatal arterial ischemic stroke

BACKGROUND AND PURPOSE: The objective was to investigate the role of infant and maternal thrombophilia in a cohort of mothers and infants presenting with perinatal arterial ischemic stroke. METHODS: Forty-seven infants with clinically and radiologically confirmed perinatal arterial ischemic stroke underwent thrombophilia workup: factor V Leiden (FVL), PII20210A mutation, Methylene-tetrahydrofolate reductase 677T polymorphism, protein C, protein S, antithrombin, FVIII, and antiphospholipid antibodies. Thrombophilia data were available for 23 motherinfant pairs and compared with control populations to evaluate the risk for PAS. RESULTS: Thirty of 47 (64%) infants and 15 of 22 mothers (68%) had evidence of thrombophilia. In 18 of 23 (78%) motherinfant pairs, there was at least 1 thrombophilic risk factor, but 15 pairs were mismatched in pathology. Among infants, FVL, protein C deficiency, and presence of antiphospholipid antibodies prevailed (OR, 4.2; 95% CI, 1.511.3; OR, 12.2; 95% CI, 2.559.9; OR, 4.1; 95% CI, 1.412.2, respectively). Interestingly FVL prevailed in almost one-third of mothers (OR, 8.5; 95% CI, 4.117.5) and 18% of mothers had antiphospholipid antibodies (OR, 3.8l; 95% CI, 1.510.0). CONCLUSIONS: Maternal and neonatal thrombophilia, especially presence of FVL or antiphospholipid antibodies, may be important in the pathogenesis of perinatal arterial ischemic stroke. The nature of thrombophilic motherinfant risk potential interactions warrants further investigation.